{"id":"ifn-beta-48-weeks","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Flu-like symptoms (fever, chills, myalgia)"},{"rate":"20-40","effect":"Injection site reactions"},{"rate":"30-50","effect":"Headache"},{"rate":"30-40","effect":"Fatigue"},{"rate":"10-20","effect":"Elevated liver enzymes"},{"rate":"5-15","effect":"Leukopenia"},{"rate":"5-10","effect":"Depression/mood changes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IFN beta is a type I interferon that binds to the interferon-alpha/beta receptor (IFNAR) on cell surfaces, triggering JAK-STAT signaling pathways. This leads to upregulation of interferon-stimulated genes, enhanced natural killer cell activity, increased MHC expression, and modulation of pro-inflammatory cytokine production. The 48-week dosing regimen suggests chronic immunomodulation for a chronic disease indication.","oneSentence":"Interferon beta activates innate immune responses by binding to interferon-beta receptors on immune cells, enhancing antiviral and immunomodulatory activity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:33.147Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple sclerosis (relapsing-remitting or secondary progressive forms)"}]},"trialDetails":[{"nctId":"NCT01753570","phase":"PHASE3","title":"Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-12","conditions":"Chronic Hepatitis C(CHC)","enrollment":74},{"nctId":"NCT02727907","phase":"PHASE2, PHASE3","title":"Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis","status":"COMPLETED","sponsor":"Biocad","startDate":"2015-02-12","conditions":"Multiple Sclerosis","enrollment":163},{"nctId":"NCT00436826","phase":"PHASE2","title":"A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2006-11-30","conditions":"Multiple Sclerosis","enrollment":172},{"nctId":"NCT00813709","phase":"PHASE3","title":"Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2008-12","conditions":"Multiple Sclerosis, Clinically Isolated Syndrome","enrollment":402},{"nctId":"NCT01939002","phase":"PHASE3","title":"Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)","status":"COMPLETED","sponsor":"Biogen","startDate":"2013-11","conditions":"Relapsing Multiple Sclerosis","enrollment":251},{"nctId":"NCT01285401","phase":"PHASE2","title":"Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2011-02","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":260},{"nctId":"NCT01142466","phase":"PHASE4","title":"A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2005-12","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":30},{"nctId":"NCT00404352","phase":"PHASE3","title":"REbif FLEXible Dosing in Early Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2006-11","conditions":"Multiple Sclerosis","enrollment":517}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"IFN beta(48 weeks)","genericName":"IFN beta(48 weeks)","companyName":"Tanabe Pharma Corporation","companyId":"tanabe-pharma-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Interferon beta activates innate immune responses by binding to interferon-beta receptors on immune cells, enhancing antiviral and immunomodulatory activity. Used for Multiple sclerosis (relapsing-remitting or secondary progressive forms).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}